Morningstar

Kamada Ltd KMDA

Stock XTAE Rating as of Oct 16, 2026

News

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

GlobeNewswire Oct 6, 2026, 11:00:00 AM
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

GlobeNewswire Sep 17, 2026, 11:00:00 AM
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire Sep 10, 2026, 11:00:00 AM
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

GlobeNewswire Sep 3, 2026, 8:01:00 PM
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

GlobeNewswire Aug 17, 2026, 11:00:00 AM
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

GlobeNewswire Aug 12, 2026, 11:05:00 AM
Kamada Announces Planned Transition of Chief Financial Officer

GlobeNewswire Aug 12, 2026, 11:00:00 AM
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

GlobeNewswire Aug 5, 2026, 11:00:00 AM
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

GlobeNewswire Jul 20, 2026, 11:00:00 AM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.